Cargando…
Tofacitinib and newer JAK inhibitors in inflammatory bowel disease—where we are and where we are going
Inflammatory bowel diseases, comprising ulcerative colitis (UC) and Crohn’s disease, are chronic, immune-mediated and progressive inflammatory disorders affecting the gastrointestinal tract. Tofacitinib is the first oral small-molecule Janus kinase (JAK) inhibitor licensed and approved by the Nation...
Autores principales: | Liu, Eleanor, Aslam, Nasar, Nigam, Gaurav, Limdi, Jimmy K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioExcel Publishing Ltd
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9007061/ https://www.ncbi.nlm.nih.gov/pubmed/35462642 http://dx.doi.org/10.7573/dic.2021-11-4 |
Ejemplares similares
-
Cannabinoids for treating inflammatory bowel diseases: where are we and where do we go?
por: Hasenoehrl, Carina, et al.
Publicado: (2017) -
Bcr-Abl Allosteric Inhibitors: Where We Are and Where We Are Going to
por: Carofiglio, Francesca, et al.
Publicado: (2020) -
The Clusmy Child: Where Are We and Where Are We Going?
por: Hadders-Algra, Mijna, et al.
Publicado: (2003) -
European HEPnet: where we are and where we are going
por: Carpenter, B E, et al.
Publicado: (1990) -
Iron health: where are we and where are we going?
por: Gotardo, Glória Ines Beal
Publicado: (2011)